| Literature DB >> 33518104 |
Quail Das1, Joshua Tang2, Xianhua Yin2, Kelly Ross3, Keith Warriner4, Massimo F Marcone4, Moussa S Diarra5.
Abstract
With the pressure to reduce antibiotics use in poultry production, cost-effective alternative products need to be developed to enhance the bird's immunity. The present study evaluated the efficacy of cranberry fruit by-products to modulate immunity in broiler chickens. Broiler Cobb 500 chicks were fed a control basal diet, basal diet supplemented with bacitracin (BACI, 55 ppm), cranberry pomace at 1% and 2% (CP2), or cranberry pomace ethanolic extract at 150 and 300 ppm (COH300) for 30 d. Blood sera were analyzed at days 21 and 28 of age for Ig levels by ELISA. The innate and adaptive immune-related gene expression levels in the liver and bursa of Fabricius were investigated at 21 d of age by quantitative polymerase chain reaction arrays. At day 21, the highest IgY level was found in the blood serum of the CP2-fed birds. In the liver, 13 of the 22 differentially expressed genes were downregulated across all treatments compared with the control. Expression of genes belonging to innate immunity such as caspase 1 apoptosis-related cysteine peptidase, chemokine receptor 5, interferon gamma, myeloid differentiation primary response gene 88, and Toll-like receptor 3 were significantly downregulated mainly in BACI- and COH300-fed birds. In the bursa, 5 of 9 genes associated with the innate immunity were differentially expressed. The expression of anti-inflammatory IL-10 gene was upregulated in all treatment groups in bursa compared with the control. The expression of transferrin gene was significantly upregulated in livers of birds fed COH300 and in bursa of birds fed BACI, indicating feeding practices and organ-dependant modulation of this gene in broiler. Overall results of this study showed that cranberry product feed supplementation modulated the innate immune and suppressed proinflammatory cytokines in broilers, providing a platform for future investigations to develop berry products in poultry feeding. CrownEntities:
Keywords: broiler; cranberry pomace; liver and bursa immunity; serum Ig
Mesh:
Substances:
Year: 2020 PMID: 33518104 PMCID: PMC7858021 DOI: 10.1016/j.psj.2020.09.044
Source DB: PubMed Journal: Poult Sci ISSN: 0032-5791 Impact factor: 3.352
Composition and antioxidant activities of organic cranberry pomace (CP) and its ethanol soluble extractives (COH).
| Parameter | CP | COH |
|---|---|---|
| Total lipids | 4.41 ± 0.38 | 3.86 ± 0.11 |
| Total protein | 5.76 ± 0.23 | 0.60 ± 0.03 |
| Total carbohydrates | 88.78 | 94.75 |
| Total phenolics | 24.87 ± 0.66 | 54.35 ± 0.85 |
| Tartaric esters | 2.77 ± 0.04 | 10.29 ± 0.41 |
| Flavonols | 3.08 ± 0.06 | 11.74 ± 0.48 |
| Anthocyanins | 4.46 ± 0.17 | 11.14 ± 0.39 |
| Tannins | 21.86 ± 0.68 | 48.09 ± 1.26 |
| Antioxidant activity | 104.51 ± 3.52 | 243.61 ± 5.11 |
DM basis.
(mg gallic acid eq./g).
(mg caffeic acid eq./g).
(mg quercetin eq./g).
(mg cyanidin-3-glucoside eq./g).
(μmol Trolox eq./g).
Anthocyanins of organic cranberry pomace (CP) and its ethanol soluble extractives (COH).
| Anthocyanin | CP (mg/g dw) | Total anthocyanin (%) | COH (mg/g dw) | Total anthocyanin (%) |
|---|---|---|---|---|
| Delphinidin 3-galactoside | 0.02 ± 0.00 | 0.38 | 0.04 ± 0.00 | 0.38 |
| Cyanidin 3-galactoside | 1.20 ± 0.13 | 25.31 | 2.05 ± 0.04 | 22.13 |
| Cyanidin 3-arabinoside | 0.85 ± 0.09 | 17.9 | 1.47 ± 0.03 | 15.8 |
| Peonidin 3-galactoside | 1.58 ± 0.16 | 33.24 | 2.75 ± 0.04 | 29.71 |
| Peonidin 3-arabinoside | 0.68 ± 0.07 | 14.26 | 1.14 ± 0.02 | 12.34 |
| Peonidin 3-glucoside | 0.17 ± 0.02 | 3.53 | 0.50 ± 0.00 | 5.38 |
| Malvidin 3-glucoside | – | – | 0.09 ± 0.00 | 0.93 |
| Malvidin 3-arabinoside | 0.06 ± 0.01 | 1.34 | 0.13 ± 0.00 | 1.37 |
| Unknown acetylated anthocyanins D | 0.02 ± 0.00 | 0.44 | 0.18 ± 0.01 | 1.9 |
– (not detected).
mg/g dw: mg/g dry weight.
The list of studied chicken innate and adaptive immune genes.
| Refseq | Gene symbol | Description |
|---|---|---|
| NM_205405 | Complement component 3 | |
| XM_004950900 | Complement component 5a receptor 1 | |
| NM_001024830 | Cathelicidin antimicrobial peptide | |
| NM_204924 | Caspase 1, apoptosis-related cysteine peptidase (IL 1, beta, convertase) | |
| NM_204720 | Chemokine (C-C motif) ligand 4 | |
| NM_001045832 | Chemokine (C-C motif) ligand 5 | |
| XM_004939483 | Chemokine (C-C motif) receptor 4 | |
| NM_001045834 | Chemokine (C-C motif) receptor 5 | |
| NM_001114081 | Chemokine (C-C motif) receptor 6 | |
| NM_001030991 | Chemokine (C-C motif) receptor 8 | |
| NM_001139478 | CD14 molecule | |
| NM_205311 | CD28 molecule | |
| NM_204649 | CD4 molecule | |
| NM_204665 | CD40 molecule, TNF receptor superfamily member 5 | |
| NM_204733 | CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) | |
| NM_001079739 | CD80 molecule | |
| NM_001037839 | CD86 molecule | |
| NM_205235 | CD8a molecule | |
| NM_001039564 | C-reactive protein, pentraxin-related | |
| NM_001007078 | Granulocyte-macrophage colony-stimulating factor | |
| NM_001199487 | Fas (TNF receptor superfamily, member 6) | |
| NM_001031559 | Fas ligand (TNF superfamily, member 6) | |
| NM_001008444 | GATA-binding protein 3 | |
| NM_001193638 | Interferon induced with helicase C domain 1 | |
| NM_205427 | Interferon | |
| NM_204859 | Interferon (alfa, beta and omega) receptor 1 | |
| NM_001024836 | Interferon beta | |
| NM_205149 | Interferon, gamma | |
| NM_001130387 | Interferon gamma receptor 1 | |
| NM_001004414 | IL 10 | |
| NM_001007085 | IL 13 | |
| NM_204571 | IL 15 | |
| NM_204608 | IL 18 (interferon gamma–inducing factor) | |
| NM_204524 | IL 1, beta | |
| NM_205485 | IL 1 receptor, type I | |
| NM_204153 | IL 2 | |
| NM_001007079 | IL 4 | |
| NM_001007084 | IL 5 | |
| NM_204628 | IL 6 (IL, beta 2) | |
| NM_205018 | IL 8 | |
| NM_205415 | Interferon regulatory factor 1 | |
| XM_417990 | Interferon regulatory factor 6 | |
| NM_205372 | Interferon regulatory factor 7 | |
| NM_205251 | Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) | |
| NM_001030538 | Janus kinase 2 (a protein tyrosine kinase) | |
| NM_001031289 | Jun proto-oncogene | |
| NM_204267 | Lipopolysaccharide-induced TNF factor | |
| XM_003641945 | Interleukin-17C-like | |
| XM_003643566 | Signal transducer and transcription activator 6-like | |
| XM_427671 | Similar to MGC83617 protein | |
| NM_205304 | Transferrin | |
| XM_004939913 | Lymphocyte antigen 96 | |
| NM_205281 | Lysozyme (renal amyloidosis) | |
| NM_204150 | Mitogen-activated protein kinase 1 | |
| NM_204349 | Mannose-binding lectin (protein C) 2, soluble | |
| XM_415716 | Myeloperoxidase | |
| NM_204609 | Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) | |
| NM_001030962 | Myeloid differentiation primary response gene (88) | |
| NM_205134 | Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 | |
| NM_001001472 | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | |
| XM_001233261 | NLR family, pyrin domain containing 3 | |
| XM_418777 | Nucleotide-binding oligomerization domain containing 1 | |
| NM_001167718 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | |
| NM_001031188 | Recombination activating gene 1 | |
| NM_204964 | Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 | |
| NM_001012914 | Signal transducer and activator of transcription 1, 91 kDa | |
| NM_001030931 | Signal transducer and activator of transcription 3 (acute-phase response factor) | |
| NM_001267555 | Signal transducer and activator of transcription 4 | |
| NM_001081506 | Toll-like receptor adaptor molecule 1 | |
| NM_001037835 | Toll-like receptor 15 | |
| NM_001030558 | Toll-like receptor 21 | |
| NM_001161650 | Toll-like receptor 2 family member B | |
| NM_001011691 | Toll-like receptor 3 | |
| NM_001030693 | Toll-like receptor 4 | |
| NM_001024586 | Toll-like receptor 5 | |
| NM_001007488 | Toll-like receptor 1 family member A | |
| NM_001011688 | Toll-like receptor 7 | |
| XM_421089 | TNF receptor-associated factor 6 | |
| NM_205518 | Actin, beta | |
| XM_425746 | Hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) | |
| XM_417846 | Hydroxymethylbilane synthase | |
| NM_001007479 | Ribosomal protein L4 | |
| XM_001234599 | Ubiquitin C | |
| NM_204592 | Caspase 8, apoptosis-related cysteine peptidase | |
| NM_204510 | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | |
| NM_204617 | Chemokine (C-X-C motif) receptor 4 | |
| NM_001030738 | IL-1 receptor–associated kinase 4 | |
| XM_001232615 | Mitogen-activated protein kinase 14 | |
| XM_001233168 | Mitogen-activated protein kinase 8 | |
| SA_00517 | GGDC | Chicken Genomic DNA Contamination |
| SA_00104 | RTC | Reverse Transcription Control |
| SA_00104 | RTC | Reverse Transcription Control |
| SA_00104 | RTC | Reverse Transcription Control |
| SA_00103 | PPC | Positive PCR Control |
| SA_00103 | PPC | Positive PCR Control |
| SA_00103 | PPC | Positive PCR Control |
Housekeeping gene for bursa.
Housekeeping gene for liver.
Internal control genes.
Figure 1The concentrations (ng/μL) of Ig (A) IgY, (B) IgM, and (C) IgA in blood sera of broilers on both ages of d 21 and d 28 treated with different feed treatments. Cranberry products were administrated via feed. Data represent least square means ± SEM of 6 replicates/treatment (n = 6 pens of at least 40 chickens/pen) arranged in a completely randomized block design. ∗ indicates significant treatment effect; ∗∗ indicates significant age (sampling day) effect on Ig profile. Abbreviations: BACI, basal diet supplemented with bacitracin; COH150, basal diet supplemented with cranberry pomace ethanolic extract at 150 ppm; COH300, basal diet supplemented with cranberry pomace ethanolic extract at 300 ppm; CP1, basal diet supplemented with cranberry pomace at 1%; CP2, basal diet supplemented with cranberry pomace at 2%.
Differentially expressed innate and adaptive immune genes from chicken liver in response to feed treatments compared with control.1,2
| Gene symbol | Fold change | ||||
|---|---|---|---|---|---|
| Bacitracin | CP1 | CP2 | COH150 | COH300 | |
| −22.55∗ | −1.13∗ | −1.72∗ | −1.10∗ | −6.41∗ | |
| −1.26∗ | −1.27∗ | −1.33∗ | −1.20∗ | −1.12∗ | |
| −1.27∗ | −1.29∗ | −1.06∗ | −1.13∗ | −1.32∗ | |
| −2.07∗ | −1.19∗ | −1.42∗ | −1.01∗ | −2.19∗ | |
| −1.63∗ | −1.32∗ | −2.11∗ | −1.48∗ | −1.35∗ | |
| −1.84∗ | −1.90∗ | −1.14∗ | −1.04∗ | −2.35∗ | |
| −1.45∗ | −1.75∗ | −3.00∗ | −1.25∗ | −2.04∗ | |
| −1.79∗ | −1.28∗ | −1.69∗ | −1.08∗ | −1.73∗ | |
| −1.76∗ | −1.45∗ | −2.08∗ | −1.12∗ | −1.06∗ | |
| −1.33∗ | −1.35∗ | −1.78∗ | −1.02∗ | −1.10∗ | |
| −1.51∗ | −1.59∗ | −1.07∗ | −1.38∗ | −1.96∗ | |
| −1.05∗ | −1.29∗ | −1.04∗ | −2.06∗ | −1.22∗ | |
| −7.97∗ | −5.19∗ | −9.35∗ | −2.86∗ | −2.04∗ | |
| −1.58∗ | −1.42∗ | −2.03∗ | −1.09∗ | −1.30∗ | |
| −1.26∗ | −1.19∗ | −1.37∗ | −2.27∗ | −1.51∗ | |
| −1.09∗ | −2.44∗ | −1.17∗ | −2.36∗ | −1.02∗ | |
| −1.41∗ | −2.66∗ | −4.00∗ | −3.01∗ | −2.89∗ | |
| −1.64∗ | −1.25∗ | −1.01∗ | −1.01∗ | −1.00∗ | |
| −5.61∗ | −3.29∗ | −3.62∗ | −2.04∗ | −4.33∗ | |
| −1.09∗ | −1.39∗ | −1.49∗ | −2.04∗ | −1.09∗ | |
| −1.16∗ | −1.18∗ | −1.25∗ | −1.18∗ | −1.37∗ | |
| −1.31∗ | −1.61∗ | −2.09∗ | −1.18∗ | −1.70∗ | |
| −1.23∗ | −1.07∗ | −1.14∗ | −1.19∗ | −1.32∗ | |
| −1.70∗ | −1.10∗ | −1.01∗ | −1.14∗ | −2.47∗ | |
| −1.24∗ | −1.23∗ | −1.26∗ | −1.09∗ | −1.22∗ | |
| −12.34∗ | −1.89∗ | −4.88∗ | −2.17∗ | −5.89∗ | |
| −1.21∗ | −2.14∗ | −1.04∗ | −2.10∗ | −1.31∗ | |
| −1.33∗ | −1.21∗ | −1.34∗ | −1.30∗ | −1.14∗ | |
| −1.19∗ | −1.89∗ | −2.11∗ | −1.03∗ | −1.75∗ | |
| −1.24∗ | −1.39∗ | −1.30∗ | −1.01∗ | −1.25∗ | |
| −3.05∗ | −1.68∗ | −2.24∗ | −2.52∗ | −1.11∗ | |
| −1.78∗ | −1.26∗ | −1.24∗ | −1.36∗ | −1.50∗ | |
| −1.39∗ | −1.13∗ | −1.28∗ | −1.04∗ | −1.59∗ | |
∗Indicates fold change values that are significantly different compared with control (P < 0.05), ǀFCǀ ≥ 1.2.
Basal diet supplemented with bacitracin (BACI, 55 ppm), cranberry pomace at 1% (CP1) and 2% (CP2), and cranberry pomace ethanolic extract at 150 (COH150) and 300 ppm (COH300).
Fold change (upregulation as a positive value or downregulation as a negative value) of genes in birds supplemented with 5 different feed treatments compared to control.
Differentially expressed innate and adaptive immune genes from chicken bursa in response to feed treatments compared to control.1,2
| Gene symbol | Fold change | ||||
|---|---|---|---|---|---|
| Bacitracin | CP1 | CP2 | COH150 | COH300 | |
| −1.17∗ | −1.31∗ | −1.67∗ | −1.39∗ | −2.27∗ | |
| −1.22∗ | −1.16∗ | −1.12∗ | −1.56∗ | −1.35∗ | |
| −1.20∗ | −1.15∗ | −1.48∗ | −2.09∗ | −1.39∗ | |
| −1.15∗ | −1.07∗ | −1.06∗ | −2.58∗ | −1.07∗ | |
| −1.59∗ | −1.79∗ | −2.40∗ | −1.09∗ | −1.65∗ | |
| −1.30∗ | −1.04∗ | −1.26∗ | −2.16∗ | −1.34∗ | |
| −1.78∗ | −1.24∗ | −1.87∗ | −2.98∗ | −1.86∗ | |
| −1.02∗ | −1.06∗ | −9.81∗ | −1.13∗ | −1.24∗ | |
| −1.45∗ | −1.02∗ | −1.19∗ | −2.22∗ | −1.08∗ | |
| −1.13∗ | −1.32∗ | −1.20∗ | −2.33∗ | −1.12∗ | |
| −1.59∗ | −1.32∗ | −1.10∗ | −1.38∗ | −1.72∗ | |
| −1.10∗ | −1.00∗ | −1.19∗ | −2.50∗ | −1.30∗ | |
| −1.00∗ | −1.74∗ | −1.14∗ | −1.58∗ | −1.28∗ | |
| −2.46∗ | −1.52∗ | −5.61∗ | −3.82∗ | −2.48∗ | |
| −4.06∗ | −3.07∗ | −4.67∗ | −2.81∗ | −2.88∗ | |
| −1.03∗ | −1.44∗ | −1.09∗ | −2.11∗ | −1.19∗ | |
| −2.10∗ | −1.54∗ | −1.34∗ | −3.42∗ | −1.67∗ | |
| −1.11∗ | −1.03∗ | −1.09∗ | −1.03∗ | −1.13∗ | |
| −1.51∗ | −1.01∗ | −1.52∗ | −2.99∗ | −1.31∗ | |
| −1.13∗ | −1.00∗ | −1.16∗ | −1.06∗ | −1.13∗ | |
| −1.59∗ | −1.80∗ | −1.63∗ | −4.51∗ | −1.78∗ | |
| −1.21∗ | −1.06∗ | −1.16∗ | −2.66∗ | −1.09∗ | |
| −1.19∗ | −1.21∗ | −1.27∗ | −1.67∗ | −1.52∗ | |
| −1.27∗ | −1.23∗ | −1.54∗ | −1.13∗ | −1.23∗ | |
∗Indicates fold change values that are significantly different compared with control (P < 0.05), ǀFCǀ ≥ 1.2.
Basal diet supplemented with bacitracin (BACI, 55 ppm), cranberry pomace at 1% (CP1) and 2% (CP2), and cranberry pomace ethanolic extract at 150 (COH150) and 300 ppm (COH300).
Fold change (upregulation as a positive value or downregulation as a negative value) of genes in birds supplemented with 5 different feed treatments compared with control.